Streetbeat News

Analyst Ratings

BCOV

In the last quarter, Brightcove (NASDAQ:BCOV) received 3 bullish and 1 indifferent analyst ratings, with an average price target of $8.12, a 16% increase from the previous average of $7.00. The current price of Brightcove is $4.27.

Portfolio Pulse from Benzinga Insights

June 12, 2023 | 12:04 pm

CCL

Over the past 3 months, 9 analysts have published their opinion on Carnival (NYSE:CCL) stock, with an average 12-month price target of $12.67, a 10.17% increase from the previous average of $11.50.

Portfolio Pulse from Benzinga Insights

June 12, 2023 | 12:02 pm

CCL

CUK

Carnival shares are trading higher following an upgrade by JP Morgan analysts.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2023 | 11:53 am

EXAS

HD

LPTV

SMTC

YEXT

Five stock picks from Wall Street's most accurate analysts include Home Depot, Exact Sciences, Loop Media, Semtech, and Yext. These analysts have accuracy rates ranging from 84% to 87% and see potential upsides in the stocks they cover.

Portfolio Pulse from Lisa Levin

June 12, 2023 | 11:52 am

IMGN

Canaccord Genuity analyst John Newman has reiterated a Buy rating on Immunogen (NASDAQ: IMGN) and maintained a $19 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 11:47 am

ILMN

Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating on Illumina (NASDAQ:ILMN) and maintained a $300 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 11:46 am

BIIB

Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Biogen (NASDAQ:BIIB) and raises the price target from $330 to $350.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 11:45 am

APRN

Benchmark analyst Daniel Kurnos maintains a Buy rating on Blue Apron Holdings (NYSE:APRN) and raises the price target from $5 to $16.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 11:41 am

HUMA

Benchmark analyst Bruce Jackson reiterates a Buy rating on Humacyte (NASDAQ:HUMA) and maintains a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 11:40 am

TMUS

Benchmark analyst Matthew Harrigan reiterates a Buy rating on T-Mobile US (NASDAQ:TMUS) and maintains a $200 price target.

Portfolio Pulse from richadhand@benzinga.com

June 12, 2023 | 11:39 am